Tempest Q3 EPS $(0.48); Cash And Equivalents At End Of Q3 $11.1M
Portfolio Pulse from Benzinga Newsdesk
Tempest Therapeutics reported Q3 earnings per share (EPS) of $(0.48). The company's cash and equivalents at the end of Q3 stood at $11.1M.
November 08, 2023 | 10:35 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Tempest Therapeutics reported a Q3 EPS of $(0.48). The company's cash and equivalents at the end of Q3 were $11.1M.
The reported Q3 EPS of $(0.48) indicates a loss, which could negatively impact investor sentiment and potentially lead to a decrease in the company's stock price in the short term. The company's cash and equivalents at the end of Q3 were $11.1M, which provides some liquidity but may not be sufficient depending on the company's burn rate.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100